AIRS vs CNMD
AIRS: AirSculpt operates a proprietary, minimally invasive body contouring platform that removes fat and tightens skin through 31 treatment centers, competing with traditional liposuction and non-surgical fat reduction while benefiting from rising GLP-1 drug adoption. CNMD: CONMED makes surgical visualization, insufflation, and monitoring devices that enable surgeons to perform minimally invasive procedures more effectively and safely.
Side-by-side fundamentals
| Metric | AIRS | CNMD | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $4.82 | $42.00 | |
| Market cap as of 2026-07-23 | $340M | $1.3B | |
| P/E as of 2026-07-23 | n/a | 22.91 | |
| Net margin as of 2026-07-23 | -7.4% | +4.0% | CNMD higher |
| Gross margin as of 2026-07-23 | +66.1% | +55.2% | AIRS higher |
| Operating margin as of 2026-07-23 | -7.8% | +8.2% | CNMD higher |
| ROE as of 2026-07-23 | -12.4% | +5.4% | CNMD higher |
| ROA as of 2026-07-23 | -5.9% | +2.4% | CNMD higher |
| Debt / equity as of 2026-07-23 | 0.45 | 0.85 | AIRS lower |
| Revenue growth (YoY) as of 2026-07-23 | -11.8% | +4.1% | CNMD higher |
| Revenue CAGR (3y) SEC XBRL | -3.5% | +9.6% | CNMD higher |
| Dividend yield as of 2026-07-23 | +0.0% | +1.9% | CNMD higher |
| Dividend streak (yrs) SEC XBRL | 1 | 1 | Tie |
| Beta as of 2026-07-23 | 2.40 | 0.93 | |
| 1-year return as of 2026-07-22 close | -13.4% | -12.5% | CNMD higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.